Because of the great deal of data showing that CD46, CD55, and CD59 expression are linked to worse clinical outcomes, and are in some cases highly specific for tumor cells, many approaches to block mCRP expression on tumor cells have been studied. This evidence concerns the gene CD46 and neoplasm.